Ruxotor (Ruxolitinib 10 mg)

Name: Ruxotor (Ruxolitinib 10 mg)
Brand: Meds For Cancer
SKU: 3618
Price: $150 USD
Availability: BackOrder

Ruxotor (Ruxolitinib 10 mg) is used to treat patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. The effectiveness of this medication in children has not been established.

Ruxolitinib Mechanism of Action

Ruxotor is a Janus Kinase (JAK) Inhibitor, which works by inhibiting JAK1 and JAK2 when they become overactive in a blood cancer called myelofibrosis (MF). By blocking those kinases, Ruxotor helps restore balance in blood cell production and reduces inflammation.

Ruxolitinib Dosage and Administration

The starting dose is 20 mg Ruxotor tablet orally twice daily for patients with a platelet count greater than 200 x 10^9/L.
15 mg orally twice daily for patients with platelet count between 100 X 109 /L and 200 X 109 /L.
Perform a CBC (complete blood count) test every 2 to 4 weeks until the doses are stabilized.
Your healthcare provider may modify the dosage for thrombocytopenia.
The maximum daily dose is 25 mg twice orally. Healthcare providers may increase the dose based on treatment response.
Take the medication with or without food.
Do not drink grapefruit juice while taking Ruxotor 10 mg.
Do not take a double dose if you miss a dose. Take the regular dose the next day.

Possible side effects of Ruxolitinib tablets

Ruxotor can cause low platelet count, low red blood cell count, and low white blood cell count. Your health care provider will perform blood tests before, during, and after the treatment to monitor progression.
The medication can cause mild to serious infections. Tell your healthcare provider right away if you experience any severe infections.
It can also cause dizziness, headache, unusual bleeding, chills, aches, fever, nausea, shortness of breath, and fatigue.

Tell your healthcare provider before taking Ruxotor (Ruxolitinib 10 mg)

Before taking Ruxotor, tell your healthcare provider if you

have an infection
have had liver or kidney problems
are on dialysis. Ruxotor tablet should be taken after dialysis.
have other medical problems
are pregnant or planning to become pregnant
are breastfeeding or planning to breastfeed
are taking any medicines, including fungal infection, bacterial infection, and HIV-AIDS medicines

Ruxotor 10 mg tablets storage Information

Store Ruxolitinib tablets in a dry place at room temperature away from children and pets.

Ruxolitinib 10 mg Price in the UK

The price of Ruxolitinib 10 mg in the UK depends on the brand (JAKAFI) and biosimilars. Biosimilar Ruxotor is manufactured by Everest Pharmaceuticals, which may cost between $200-$250, depending on the manufacturer.

What are the ingredients in Ruxotor?

Each Ruxotor 10 mg film-coated tablet contains the active ingredient equivalent to 10 mg Ruxolitinib and inactive ingredients microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silicon dioxide, sodium starch glycolate, povidone, and hydroxypropyl cellulose.

When was Ruxolitinib approved by the FDA?

It was approved initially by the FDA in 2011 for the treatment of Janus kinase in myelofibrosis blood cancer.

How effective is Ruxotor 10 mg?

Studies have shown that Ruxotor can help shrink the spleen, reduce symptoms, and lower the levels of certain inflammatory substances (like TNF-α and IL-6) in the blood.

How does Ruxolitinib get into the cell?

Ruxolitinib, taken orally, is absorbed into the bloodstream and travels to affected tissues. As a small molecule, it easily enters cells by diffusion through the cell membrane. Inside, it blocks the overactive JAK1 and JAK2 proteins, helping reduce abnormal blood cell production and inflammation in myelofibrosis.